- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02248688
Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically (GETLEAN)
Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically (GET LEAN)
Study Overview
Status
Intervention / Treatment
Detailed Description
Beadblock will be used intraarterially to occlude in this case the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone ghrelin (one of the hormones responsible for appetite) is produced. Ghrelin is a 28 amino acid hunger stimulating peptide and hormone that is produced mainly by P/D1 cells lining the fundus of the stomach and epsilon cells of the pancreas. Ghrelin has emerged as the first identified circulating hunger hormone. Ghrelin is also the only known circulating orexigen, or appetite enhancing hormone.
Left gastric artery embolization may be a minimally invasive alternative to the current surgical treatment of gastric bypass or reduction surgery. These treatments have known serious complications including anastomotic leaks, bowel obstruction, paralytic ileus, deep vein thrombosis, pulmonary embolism, gastrointestinal bleeding, dumping syndrome, and anesthesia risks resulting in morbidity and mortality.
Literature review for gastric artery embolization
Transarterial embolization is a common interventional procedure used to treat a variety of medical conditions. In the image-guided procedure, an embolic, or obstructive, agent is inserted through a catheter and placed inside an artery to prevent blood flow in an artery or to a specific area of the body. Types of embolic agents include beads, coils, gel foam,as well as other materials and devices.
Gastric artery embolization has been used since the 1970's to treat life threatening gastric hemorrhage. This is commonly accepted as standard of care and has been life saving for thousands of patients. It is even deemed to be effective enough to be used empirically in the setting of angiographically negative life threatening hemorrhage (as a reflection of its safety margin).
Recent animal studies over the past several years in porcine and canine models have shown that gastric artery embolization results in the suppression of ghrelin levels and weight loss.
Arepally, et al. (2008) first described the technique of gastric artery embolization to reduce weight gain. In a controlled study, he used sodium morrhuate within a porcine model with resultant lower ghrelin levels and significantly blunted weight gain (in otherwise rapidly growing young swine).
Paxton, et al. (SIR abstract in 2012, later published in 2013 and 2014) described the technique of 40 micron microsphere particle embolization in a similar porcine model that also resulted in lowered ghrelin levels and reduced weight gain. Also noted there was no duodenal upregulation for ghrelin.
Bawudun et al. (2012) described a technique of left gastric embolization using mixture of bleomycin and lipiodol versus polyvinyl alcohol 500-700 micron particles to create weight loss in a canine model without gastric ulceration. In addition, he demonstrated significant reduction in subcutaneous fat and plasma ghrelin.
Kipshidze, et al. (2013) performed the first in man study reported at the annual meeting of the American College of Cardiology that showed an average of 45lbs of weight loss in 6 months and reduced ghrelin levels in 5 patients with no complications (with endoscopic follow-up) in this small series using BeadBlock 300-500 micron particles. According to personal correspondence with the author of this study the weight loss is sustained for at least 1 year with no complications in these 5 patients. He also noted that an additional 7 patients have been treated without complications.
A recent retrospective case control study presented at the 2013 Radiological Society of North American annual meeting found that there was an average of 7.9% decrease in body weight (at 3 months) in 15 patients who underwent left gastric artery embolization for life threatening hemorrhage compared to 1.2% (P=0.001) for age matched controls (who underwent embolization other than the left gastric artery for upper gastrointestinal bleeding).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Dayton, Ohio, United States, 45409
- Dayton Interventional Radiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Morbid obesity with a BMI ≥ 40 Age ≥ 22years Ability to lay supine on an angiographic table <400lbs due to table weight limits Appropriate anesthesia risk as determined by certified anesthesia provider evaluation preprocedure.
Willing, able and mentally competent to provide written informed consent (to ensure that all study subjects demonstrate an understanding of the risks of the procedure and also participate in the informed consent).
Subjects who have failed previous attempts at weight loss through diet, exercise, and behavior modification (as it is recommended that conservative options, such as supervised low calorie diets combined with behavior therapy and exercise, should be attempted prior to enrolling in this study).
Exclusion Criteria:
Less than 22 years of age Major surgery within the past eight weeks Previous gastric, pancreatic, hepatic and splenic surgery Previous radiation therapy to the left or right upper quadrant Previous gastric, hepatic, or splenic embolization Any history of portal venous hypertension Serum creatinine > 1.8 mg/dL History of kidney problems Pregnant or intend to become pregnant within one year History of severe bleeding disorder (platelet count less than 40,000) Allergy to materials in the embolic agents (acrylamido polyvinyl alcohol macromer) Enrolled in another study Any patient who has a history of allergic reaction to iodinated contrast Abnormal baseline gastric emptying study Patients taking anti-coagulants or antiplatelet drugs Patients currently taking or requiring chronic use of NSAID or steroid medications Patients with any chronic upper gastrointestinal complaints such as pain, nausea or vomiting Patients with any history of peptic ulcer disease Patients with any indication of gastrointestinal bleeding as documented by positive stool guaiac and complete blood count with abnormalities.
Patients with any contraindications for monitored anesthesia care or general surgery Patients with secondary causes of obesity such as Cushing's disease and hypothyroidism Patients with active substance abuse or alcoholism Patients with defined noncompliance with previous medical care Patients with certain psychiatric disorders such as schizophrenia, borderline personality disorder, and uncontrolled depression, and mental/cognitive impairment that limits the individual's ability to understand the proposed therapy.
Subjects with mesenteric atherosclerotic disease or abdominal angina should be excluded due to safety concerns.
Patients with hiatal hernia Patients with known aortic disease, such as dissection or aneurysm Patients with comorbidity such as cancer, peripheral arterial disease or other cardiovascular disease Patients with any abnormality on their baseline EGD Patients with a CT Angiogram demonstrate an anatomical variant in left gastric artery anatomy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Embolic Agent - BeadBlock
Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.
|
Beadblock will be used intraarterially to occlude the left gastric artery and its branches.
The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Weight Average 6 Months Post-Procedure
Time Frame: 6-Month
|
The mean body weight of all 5 participants at 6-Months post-procedure.
|
6-Month
|
Body Weight Average 12 Months Post-Procedure
Time Frame: 12-Month
|
The mean body weight of all 5 participants at 12-Months post-procedure.
|
12-Month
|
Change in Average Body Weight From Baseline at 6 Months Post-Procedure
Time Frame: Baseline, 6 Months
|
Average change in body weight lost. Calculated as the average of participants: (6-Month Post-Procedure Weight in lbs.) - (Baseline Weight in lbs.) |
Baseline, 6 Months
|
Change in Average Body Weight From Baseline at 12 Months Post-Procedure
Time Frame: Baseline, 12 Months
|
Average change in body weight lost. Calculated as the average of participants: (12-Month Post-Procedure Weight in lbs.) - (Baseline Weight in lbs.) |
Baseline, 12 Months
|
Percentage of Excess Body Weight Loss at 6 Months Post-Procedure
Time Frame: Baseline, 6 Month
|
Calculated as the average of participants: (((Baseline Weight in lbs.) - (6 Month Post-Procedure Weigh in lbs.))/((Baseline Weight in lbs.) - (Ideal Body Weight in lbs.))) |
Baseline, 6 Month
|
Percentage of Excess Body Weight Loss at 12 Months Post-Procedure
Time Frame: Baseline, 12 Month
|
Calculated as the average of participants: (((Baseline Weight in lbs.) - (12 Month Post-Procedure Weigh in lbs.))/((Baseline Weight in lbs.) - (Ideal Body Weight in lbs.))) |
Baseline, 12 Month
|
Average Ghrelin Hormone Levels at 6 Months Post-Procedure
Time Frame: 6-Month
|
The mean of participant's 6-Month post-procedure Ghrelin levels.
|
6-Month
|
Average Ghrelin Hormone Levels at 12 Months Post-Procedure
Time Frame: 12-Month
|
The mean of participant's 12-Month post-procedure Ghrelin levels.
|
12-Month
|
Percentage Change in Ghrelin Hormone Levels From Baseline at 6 Months Post-Procedure
Time Frame: 6-Month, Baseline
|
Calculated as the average of participants: (((6-Month Post-Procedure Ghrelin levels in pg/mL) - (Baseline Ghrelin levels in pg/mL))/(Baseline Ghrelin levels in pg/mL) * 100 |
6-Month, Baseline
|
Percentage Change in Ghrelin Hormone Levels From Baseline at 12 Months Post-Procedure
Time Frame: 12-Month, Baseline
|
Calculated as the average of participants: (((12-Month Post-Procedure Ghrelin levels in pg/mL) - (Baseline Ghrelin levels in pg/mL))/(Baseline Ghrelin levels in pg/mL) * 100 |
12-Month, Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Leptin Hormone Levels at 6 Months Post-Procedure
Time Frame: 6-Month
|
The mean of participant's 6-month post-procedure Leptin levels.
|
6-Month
|
Average Leptin Hormone Levels at 12 Months Post-Procedure
Time Frame: 12-Month
|
The mean of participant's 12-month post-procedure Leptin levels.
|
12-Month
|
Percentage Change in Leptin Hormone Levels From Baseline at 6 Months Post-Procedure
Time Frame: 6-Month, Baseline
|
Calculated as the average of participants: (((6-Month Post-Procedure Leptin levels in ng/mL) - (Baseline Leptin levels in ng/mL))/(Baseline Leptin levels in ng/mL) * 100 |
6-Month, Baseline
|
Percentage Change in Leptin Hormone Levels From Baseline at 12 Months Post-Procedure
Time Frame: 12-Month, Baseline
|
Calculated as the average of participants: (((12-Month Post-Procedure Leptin levels in ng/mL) - (Baseline Leptin levels in ng/mL))/(Baseline Leptin levels in ng/mL) * 100 |
12-Month, Baseline
|
Average Cholecystokinin (CCK) Hormone Levels at 6 Months Post-Procedure
Time Frame: 6-Month
|
The mean of participant's 6-month post-procedure CCK levels.
|
6-Month
|
Average Cholecystokinin (CCK) Hormone Levels at 12 Months Post-Procedure
Time Frame: 12-Month
|
The mean of participant's 12-month post-procedure CCK levels.
|
12-Month
|
Percentage Change in Cholecystokinin (CCK) Hormone Levels From Baseline at 6 Months Post-Procedure
Time Frame: 6-Month, Baseline
|
Calculated as the average of participants: (((6-Month Post-Procedure CCK levels in pg/mL) - (Baseline CCK levels in pg/mL))/(Baseline CCK levels in pg/mL) * 100 |
6-Month, Baseline
|
Percentage Change in Cholecystokinin (CCK) Hormone Levels From Baseline at 12 Months Post-Procedure
Time Frame: 12-Month, Baseline
|
Calculated as the average of participants: (((12-Month Post-Procedure CCK levels in pg/mL) - (Baseline CCK levels in pg/mL))/(Baseline CCK levels in pg/mL) * 100 |
12-Month, Baseline
|
Quality of Life (QOL): Averaged Short Form (SF)-36 Version 2 Physical Component Summary (PCS) at 6 Months Post-Procedure
Time Frame: 6 Month
|
The mean of participant's SF-36 Version 2 PCS at 6 months post-procedure, ranging from 0-100; higher scores indicate better health status.
The SF-36v2 contains 8 sections total which are each calculated into individual scale scores.
A z-score is then determined for each scale score by subtracting the mean scale score of a sample of the national general population from the scale score of the individual participant being analyzed.
Each of the 8 z-scores are then multiplied by the PCS scoring coefficient, added together, multiplied by 10 and added to 50.
|
6 Month
|
Changes in QOL (Measured by SF-36v2 PCS) From Baseline at 6 Months Post-Procedure
Time Frame: 6 Month, Baseline
|
The mean of participant's SF-36 Version 2 PCS at 6 months post-procedure, ranging from 0-100; higher scores indicate better health status. The SF-36v2 contains 8 sections total which are each calculated into individual scale scores. A z-score is then determined for each scale score by subtracting the mean scale score of a sample of the national general population from the scale score of the individual participant being analyzed. Each of the 8 z-scores are then multiplied by the PCS scoring coefficient, added together, multiplied by 10 and added to 50. Changes in QOL (measured by SF-36v2 PCS) are calculated as the average of participants: (6-Month Post-Procedure SF-36v2 PCS) - (Baseline SF-36v2 PCS) |
6 Month, Baseline
|
QOL: Averaged SF-36v2 PCS at 12 Months Post-Procedure
Time Frame: 12 Month
|
The mean of participant's 12-month post-procedure Short Form-36 Version 2 Physical Component Scores, ranging from 0-100; higher scores indicate better health status.
|
12 Month
|
Changes in QOL (Measured by SF-36v2 PCS) From Baseline at 12 Months Post-Procedure
Time Frame: 12 Month, Baseline
|
The mean of participant's SF-36 Version 2 PCS at 12-months post-procedure, ranging from 0-100; higher scores indicate better health status. The SF-36v2 contains 8 sections total which are each calculated into individual scale scores. A z-score is then determined for each scale score by subtracting the mean scale score of a sample of the national general population from the scale score of the individual participant being analyzed. Each of the 8 z-scores are then multiplied by the PCS scoring coefficient, added together, multiplied by 10 and added to 50. Changes in QOL (measured by SF-36v2 PCS) are calculated as the average of participants: (12-Month Post-Procedure SF-36v2 PCS) - (Baseline SF-36v2 PCS) |
12 Month, Baseline
|
QOL: Averaged SF-36v2 MCS at 6 Months Post-Procedure
Time Frame: 6 Month
|
The mean of participant's SF-36 Version 2 MCS at 6-months post-procedure, ranging from 0-100; higher scores indicate better health status.
The SF-36v2 contains 8 sections total which are each calculated into individual scale scores.
A z-score is then determined for each scale score by subtracting the mean scale score of a sample of the national general population from the scale score of the individual participant being analyzed.
Each of the 8 z-scores are then multiplied by the MCS scoring coefficient, added together, multiplied by 10 and added to 50.
|
6 Month
|
Changes in QOL (Measured by SF-36v2 MCS) From Baseline at 6 Months Post-Procedure
Time Frame: 6 Month, Baseline
|
The mean of participant's SF-36 Version 2 MCS at 6 months post-procedure, ranging from 0-100; higher scores indicate better health status. The SF-36v2 contains 8 sections total which are each calculated into individual scale scores. A z-score is then determined for each scale score by subtracting the mean scale score of a sample of the national general population from the scale score of the individual participant being analyzed. Each of the 8 z-scores are then multiplied by the MCS scoring coefficient, added together, multiplied by 10 and added to 50. Changes in QOL (measured by SF-36v2 MCS) are calculated as the average of participants: (6-Month Post-Procedure SF-36v2 MCS) - (Baseline SF-36v2 MCS) |
6 Month, Baseline
|
QOL: Averaged SF-36v2 MCS at 12 Months Post-Procedure
Time Frame: 12 Month
|
The mean of participant's SF-36 Version 2 MCS at 12-months post-procedure, ranging from 0-100; higher scores indicate better health status.
The SF-36v2 contains 8 sections total which are each calculated into individual scale scores.
A z-score is then determined for each scale score by subtracting the mean scale score of a sample of the national general population from the scale score of the individual participant being analyzed.
Each of the 8 z-scores are then multiplied by the MCS scoring coefficient, added together, multiplied by 10 and added to 50.
|
12 Month
|
Changes in QOL (Measured by SF-36v2 MCS) From Baseline at 12 Months Post-Procedure
Time Frame: 12 Month, Baseline
|
The mean of participant's SF-36 Version 2 MCS at 12-months post-procedure, ranging from 0-100; higher scores indicate better health status. The SF-36v2 contains 8 sections total which are each calculated into individual scale scores. A z-score is then determined for each scale score by subtracting the mean scale score of a sample of the national general population from the scale score of the individual participant being analyzed. Each of the 8 z-scores are then multiplied by the MCS scoring coefficient, added together, multiplied by 10 and added to 50. Changes in QOL (measured by SF-36v2 MCS) are calculated as the average of participants: (12-Month Post-Procedure SF-36v2 MCS) - (Baseline SF-36v2 MCS) |
12 Month, Baseline
|
6-Month Post-Procedure Hemoglobin-A1c (HgA1c) Levels
Time Frame: 6-Month
|
HgA1c Levels of diabetic patient 6-Months post-procedure.
|
6-Month
|
12-Month Post-Procedure HgA1c Levels
Time Frame: 12-Month
|
HgA1c Levels of diabetic patient 12-Months post-procedure.
|
12-Month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mubin I Syed, MD, Dayton Interventional Radiology
- Study Director: Azim Shaikh, MD, MBA, Dayton Interventional Radiology
- Study Director: Sumeet Patel, Dayton Interventional Radiology
- Study Director: Feras J Deek, BS, BA, Dayton Interventional Radiology
Publications and helpful links
General Publications
- Rosch J, Dotter CT, Brown MJ. Selective arterial embolization. A new method for control of acute gastrointestinal bleeding. Radiology. 1972 Feb;102(2):303-6. doi: 10.1148/102.2.303. No abstract available.
- Bookstein JJ, Chlosta EM, Foley D, Walter JF. Transcatheter hemostasis of gastrointestinal bleeding using modified autogenous clot. Radiology. 1974 Nov;113(2):277-85. doi: 10.1148/113.2.277. No abstract available.
- Morris DC, Nichols DM, Connell DG, Burhenne HJ. Embolization of the left gastric artery in the absence of angiographic extravasation. Cardiovasc Intervent Radiol. 1986;9(4):195-8. doi: 10.1007/BF02577940.
- Arepally A, Barnett BP, Patel TH, Howland V, Boston RC, Kraitchman DL, Malayeri AA. Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology. 2008 Oct;249(1):127-33. doi: 10.1148/radiol.2491071232. Erratum In: Radiology. 2008 Dec;249(3):1083. Patel, Tarek T [corrected to Patel, Tarak H].
- Paxton BE, Alley CL, Crow JH, Burchette J, Weiss CR, Kraitchman DL, Arepally A, Kim CY. Histopathologic and immunohistochemical sequelae of bariatric embolization in a porcine model. J Vasc Interv Radiol. 2014 Mar;25(3):455-61. doi: 10.1016/j.jvir.2013.09.016. Epub 2014 Jan 21.
- Paxton BE, Kim CY, Alley CL, Crow JH, Balmadrid B, Keith CG, Kankotia RJ, Stinnett S, Arepally A. Bariatric embolization for suppression of the hunger hormone ghrelin in a porcine model. Radiology. 2013 Feb;266(2):471-9. doi: 10.1148/radiol.12120242. Epub 2012 Nov 30.
- Bawudun D, Xing Y, Liu WY, Huang YJ, Ren WX, Ma M, Xu XD, Teng GJ. Ghrelin suppression and fat loss after left gastric artery embolization in canine model. Cardiovasc Intervent Radiol. 2012 Dec;35(6):1460-6. doi: 10.1007/s00270-012-0362-8. Epub 2012 Feb 25.
- Brown KT, Friedman WN, Marks RA, Saddekni S. Gastric and hepatic infarction following embolization of the left gastric artery: case report. Radiology. 1989 Sep;172(3):731-2. doi: 10.1148/radiology.172.3.2788892.
- Castaneda-Zuniga WR, Jauregui H, Rysavy J, Amplatz K. Selective transcatheter embolization of the upper gastrointestinal tract: an experimental study. Radiology. 1978 Apr;127(1):81-3. doi: 10.1148/127.1.81.
- Bradley EL 3rd, Goldman ML. Gastric infarction after therapeutic embolization. Surgery. 1976 Apr;79(4):421-4.
- Prochaska JM, Flye MW, Johnsrude IS. Left gastric artery embolization for control of gastric bleeding: a complication. Radiology. 1973 Jun;107(3):521-2. doi: 10.1148/107.3.521. No abstract available.
- Robbins SM, Tuten TU, Clements JL, Fekete P. Angiographic diagnosis of gastric volvulus with report of a complication following left gastric artery embolization. Gastrointest Radiol. 1988;13(2):112-4. doi: 10.1007/BF01889038.
- Miller DL, Balter S, Cole PE, Lu HT, Schueler BA, Geisinger M, Berenstein A, Albert R, Georgia JD, Noonan PT, Cardella JF, St George J, Russell EJ, Malisch TW, Vogelzang RL, Miller GL 3rd, Anderson J; RAD-IR study. Radiation doses in interventional radiology procedures: the RAD-IR study: part I: overall measures of dose. J Vasc Interv Radiol. 2003 Jun;14(6):711-27. doi: 10.1097/01.rvi.0000079980.80153.4b.
- Syed MI, Morar K, Shaikh A, Craig P, Khan O, Patel S, Khabiri H. Gastric Artery Embolization Trial for the Lessening of Appetite Nonsurgically (GET LEAN): Six-Month Preliminary Data. J Vasc Interv Radiol. 2016 Oct;27(10):1502-8. doi: 10.1016/j.jvir.2016.07.010. Epub 2016 Aug 24.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Q131650
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on BeadBlock 300 - 500 Micron
-
Decathlon SEEFOR, FranceRecruiting
-
Rutgers UniversityOmniActive Health TechnologiesCompleted
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedCocaine-Related DisordersUnited States
-
RFS Pharma, LLCWithdrawnHuman Immunodeficiency Virus Infection
-
DBV TechnologiesCompletedFood AllergyUnited States, Canada
-
Dhp Korea Co., Ltd.CompletedDry Eye Syndromes | Keratoconjunctivitis SiccaKorea, Republic of
-
Tianjin Medical University Cancer Institute and...UnknownLiver Neoplasms | Hepatectomy | Nutrition TherapyChina
-
Janssen Research & Development, LLCCompleted
-
Merck KGaA, Darmstadt, GermanyCompletedCarcinoma, HepatocellularChina, Taiwan, Korea, Republic of
-
RFS Pharma, LLCTerminatedHuman Immunodeficiency Virus InfectionArgentina